Adage Capital Partners’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.9M Sell
2,167,018
-338,982
-14% -$4.72M 0.03% 429
2026
Q2
$32.7M Buy
+2,506,000
New +$25.9M 0.05% 372
2024
Q3
– Sell
-670,362
Closed -$4.77M – 952
2024
Q2
$4.77M Buy
+670,362
New +$4.46M 0.01% 718

Other funds holding CLYM

Adage Capital Partners's CLYM Position: Q3 2026 in Review

Adage Capital Partners reduced its Climb Bio (CLYM) stake by 14% in Q3 2026, selling an estimated $4.72M and leaving 2,167,018 shares worth $24.9M. The position accounts for 0.03% of the portfolio, ranked #429.

Adage Capital Partners first reported a position in CLYM in Q2 2024 and has held it in 3 quarters since. The position peaked at $32.7M in Q2 2026. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Adage Capital Partners held 2,167,018 shares of Climb Bio worth $24.9M as of Q3 2026.
  • Adage Capital Partners sold 338,982 Climb Bio shares in Q3 2026, an estimated $4.72M.
  • Climb Bio made up 0.03% of Adage Capital Partners's portfolio in Q3 2026, its #429 holding.
  • Adage Capital Partners first reported a position in Climb Bio in Q2 2024 and has held it in 3 quarters since.
  • Adage Capital Partners's Climb Bio position peaked at $32.7M in Q2 2026.
  • 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.